Mefenam (Mefenamic Acid)

Mefenamic acid works by reversibly blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin production. Lower prostaglandin levels reduce inflammation and the sensitisation of nerve endings, thereby decreasing pain perception and swelling.

The appropriate dose of Mefenam is set by the prescribing clinician based on the patient’s age, weight, severity of pain, underlying health conditions, and any concomitant medications. Dosage adjustments may be required for renal or hepatic impairment.

Safety data for mefenamic acid in pregnancy and lactation are limited. It is generally avoided during the first trimester and throughout breastfeeding unless the benefits clearly outweigh potential risks. Physicians should evaluate each case individually.

To order Mefenam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mefenam belongs to the anthranilic acid class of NSAIDs, whereas ibuprofen is a propionic acid derivative. Both inhibit COX enzymes, but mefenam may have a slightly higher risk of gastrointestinal irritation. Choice between them depends on patient tolerance, specific indications and physician preference.

Mefenam should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mefenam is administered orally, typically as a tablet or capsule taken with a full glass of water. It may be taken with or without food, but taking it with food can help minimise gastrointestinal discomfort.

The most serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, and hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, sudden loss of kidney function, or severe skin reactions.

Mefenam should be avoided in individuals with known hypersensitivity to mefenamic acid or other NSAIDs, those with active gastrointestinal ulcers, severe renal or hepatic disease, and patients taking anticoagulants without close monitoring. Pregnant women in the first trimester and breastfeeding mothers should also use it only if clearly indicated.